American Heart Journal
American Heart Journal
5 years ago

International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD, ORBIT-AF I, and ORBIT-AF II Registries

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the world. We aimed to provide comprehensive data on international patterns of AF stroke prevention treatment. Methods Demographics, comorbidities, and stroke risk of the patients in the GARFIELD-AF (n=51,270), ORBIT-AF I (n=10,132), and ORBIT-AF II (n=11,602) registries were compared (overall n=73,004 from 35 countries). Stroke prevention therapies were assessed among patients with new-onset AF (≤6weeks). Results Patients from GARFIELD-AF were less likely to be white (63% vs. 89% for ORBIT-AF I and 86% for ORBIT-AF II), or have CAD (19% vs. 36% and 27%), but had similar stroke risk (85% CHA2DS2-VASc≥2 vs. 91% and 85%), and lower bleeding risk (11% with HAS-BLED ≥3 vs. 24% and 15%). Oral anticoagulant (OAC) use was 46% and 57% for patients with a CHA2DS2-VASc=0 and 69% and 87% for CHA2DS2-VASc≥2, in GARFIELD-AF and ORBIT-AF II, respectively, but with substantial geographic heterogeneity in use of OAC (range: 30%–93% [GARFIELD-AF] and 52% -100% [ORBIT-AF II]). Among patients with new-onset AF, non-Vitamin K antagonist oral anticoagulant (NOAC) use increased over time to 45% in 2016 for GARFIELD-AF and 71% for ORBIT-AF II, while use of antiplatelet monotherapy decreased from 35% to 14% (GARFIELD-AF) and 18% to 8% (ORBIT-AF I and II). Conclusions Among new-onset AF patients, NOAC use has increased and antiplatelet monotherapy has decreased. However, anticoagulation is used frequently in low-risk patients and inconsistently in those at high-risk of stroke. Significant geographic variability in anticoagulation persists and represents an opportunity for improvement.

Publisher URL: www.sciencedirect.com/science

DOI: S0002870317302417

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.